Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine. / Theisen, Michael; Jore, Matthijs M; Sauerwein, Robert.
I: Expert Review of Vaccines, Bind 16, Nr. 4, 2017, s. 329-336.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine
AU - Theisen, Michael
AU - Jore, Matthijs M
AU - Sauerwein, Robert
PY - 2017
Y1 - 2017
N2 - Introduction: Malaria is a devastating vector-borne disease caused by the Plasmodium parasite, resulting in almost 0.5 million casualties per year. The parasite has a complex life-cycle that includes asexual replication in human red blood cells, causing symptomatic malaria, and sexual stages which are essential for the transmission to the mosquito vector. A vaccine targeting the sexual stages of the parasite and thus blocking transmission will be instrumental for the eradication of malaria. One of the leading transmission blocking vaccine candidates is the sexual stage antigen Pfs48/45.Areas covered: PubMed was searched to review the progress and future prospects for clinical development of a Pfs48/45-based subunit vaccine. We will focus on biological function, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production of recombinant protein and preclinical studies.Expert commentary: Pfs48/45 is one of the lead-candidates for a transmission blocking vaccine and should be further explored in clinical trials.
AB - Introduction: Malaria is a devastating vector-borne disease caused by the Plasmodium parasite, resulting in almost 0.5 million casualties per year. The parasite has a complex life-cycle that includes asexual replication in human red blood cells, causing symptomatic malaria, and sexual stages which are essential for the transmission to the mosquito vector. A vaccine targeting the sexual stages of the parasite and thus blocking transmission will be instrumental for the eradication of malaria. One of the leading transmission blocking vaccine candidates is the sexual stage antigen Pfs48/45.Areas covered: PubMed was searched to review the progress and future prospects for clinical development of a Pfs48/45-based subunit vaccine. We will focus on biological function, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production of recombinant protein and preclinical studies.Expert commentary: Pfs48/45 is one of the lead-candidates for a transmission blocking vaccine and should be further explored in clinical trials.
KW - Journal Article
U2 - 10.1080/14760584.2017.1276833
DO - 10.1080/14760584.2017.1276833
M3 - Journal article
C2 - 28043178
VL - 16
SP - 329
EP - 336
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
SN - 1476-0584
IS - 4
ER -
ID: 174234581